Core Insights - The company, MicroPort Robotics-B (02252.HK), has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics [1] - This approval increases the number of products approved for market by the company in the surgical robotics sector to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach areas within the body through natural orifices, which is crucial for early diagnosis and treatment of small lung nodules and early-stage cancers [1] Industry Insights - As a representative of natural orifice surgical robots, bronchoscopic surgical robots are seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic respiratory conditions, thereby expanding the clinical application boundaries of bronchoscopic interventions [2]